Opinion This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms: global protests, drug pricing, and India’s “Modicare” milestone. Protests First, the rash of protests unfolding across parts of the Middle East, Asia, and Latin America has piqued firms’ attention—not just…
See our Cookie Privacy Policy Here